other material
confidence high
sentiment positive
materiality 0.75
Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence
Greenwich LifeSciences, Inc.
- 22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).
- Patients without baseline response had 12.5% recurrence rate with median time to recurrence of 438 days.
- HER2+ patients completing GP2 primary series showed 100% DFS vs 89.4% for placebo (p=0.0338) over 5 years.
- GP2 treatment was well tolerated with no serious adverse events attributed to GLSI-100.
- Company plans Phase III trial in 2022 and exploration of GP2-specific CAR-T cell candidates.